The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study

(2016) V.J. Ludbrook et al.   BRITISH JOURNAL OF DERMATOLOGY

Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials

(2016) Bruce Strober et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis

(2016) Huaming Tan et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis

(2016) Robert Bissonnette et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy

(2016) Joel M. Kremer et al.   Arthritis & Rheumatology

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

(2015) Florence Namour et al.   CLINICAL PHARMACOKINETICS

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases

(2015) Michele W L Teng et al.   NATURE MEDICINE

Selective JAK inhibitors in development for rheumatoid arthritis

(2014) Peter Norman   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Comparisons between the 2012 New CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Equations and Other Four Approved Equations

(2014) Ying Zhu et al.   PLoS One

Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials

(2014) John D Isaacs et al.   ARTHRITIS RESEARCH & THERAPY

JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis

(2014) Leeyen Hsu et al.   Journal of Immunology Research

Janus kinase inhibitors in autoimmune diseases

(2013) John J O'Shea et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment

(2013) B. Strober et al.   BRITISH JOURNAL OF DERMATOLOGY

Tyk2 is a therapeutic target for psoriasis-like skin inflammation

(2013) M. Ishizaki et al.   INTERNATIONAL IMMUNOLOGY

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

(2012) Apostolos Kontzias et al.   CURRENT OPINION IN PHARMACOLOGY

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

(2011) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET